275 related articles for article (PubMed ID: 33388129)
1. Remdesivir: From Ebola to COVID-19.
Santoro MG; Carafoli E
Biochem Biophys Res Commun; 2021 Jan; 538():145-150. PubMed ID: 33388129
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
5. Broad-Spectrum
Lo MK; Shrivastava-Ranjan P; Chatterjee P; Flint M; Beadle JR; Valiaeva N; Murphy J; Schooley RT; Hostetler KY; Montgomery JM; Spiropoulou CF
Microbiol Spectr; 2021 Dec; 9(3):e0153721. PubMed ID: 34817209
[TBL] [Abstract][Full Text] [Related]
6. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
Yan VC; Muller FL
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111721. PubMed ID: 34252308
[TBL] [Abstract][Full Text] [Related]
7. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
8. [Remdesivir, the antiviral hope against SARS-CoV-2].
Reina J
Rev Esp Quimioter; 2020 Jun; 33(3):176-179. PubMed ID: 32239125
[TBL] [Abstract][Full Text] [Related]
9. [Remdesivir for COVID-19].
Fujita Y
Nihon Yakurigaku Zasshi; 2022; 157(1):31-37. PubMed ID: 34980809
[TBL] [Abstract][Full Text] [Related]
10. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
12. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
[TBL] [Abstract][Full Text] [Related]
13. On the molecular structure of Remdesivir for the treatment of Covid-19.
Sheikholeslami SM; Jahanbani A; Shao Z
Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
Moirangthem DS; Surbala L
Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.
Avataneo V; de Nicolò A; Cusato J; Antonucci M; Manca A; Palermiti A; Waitt C; Walimbwa S; Lamorde M; di Perri G; D'Avolio A
J Antimicrob Chemother; 2020 Jul; 75(7):1772-1777. PubMed ID: 32361744
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
Lin HXJ; Cho S; Meyyur Aravamudan V; Sanda HY; Palraj R; Molton JS; Venkatachalam I
Infection; 2021 Jun; 49(3):401-410. PubMed ID: 33389708
[TBL] [Abstract][Full Text] [Related]
17. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
Taha HR; Keewan N; Slati F; Al-Sawalha NA
Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
20. Use of remdesivir for patients with Covid-19: a review article.
Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS
Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]